tag:blogger.com,1999:blog-36634196.post3752293024722309584..comments2023-10-09T11:33:37.853-05:00Comments on The IN VIVO Blog: Plavix Pharmacogenomics: To Test or Not to Test?Chris Morrisonhttp://www.blogger.com/profile/04075266444951558159noreply@blogger.comBlogger1125tag:blogger.com,1999:blog-36634196.post-64508877308682564382009-08-28T09:58:01.334-05:002009-08-28T09:58:01.334-05:00Our sales force found a lot of initial interest am...Our sales force found a lot of initial interest among cardiologists in CYP2C19 testing last spring and it seemed like the testing was going to take off. When it came down to ordering though, they just weren't ready. Seems easy enough to figure out if you've got a 2C19 IM you'd up the dose and monitor for platelet function to protect against over medicating. For a PM you'd go to a different treatment. <br /><br />At Genelex we've been doing this testing since 2000 and have interaction software that makes the results useable for physicians. It's become clear to us that prescribers are not the drivers for PGX adoption. In the case of plavix, the PBMs like Medco, may drive it when the drug goes generic because of the dollars at stake. A pointed relabeling or Medicare payment decision would help, but are roadblocked by the widespread insistence on unrealistic and unreasonable levels of proof. The real cynics think a lawsuit or celebrity death that clearly could have been prevented by the use of PGX would bring the technology into the mainstream. <br /><br />We believe the evidence shows that variation in the three main cytochromes, 2D6, 2C9, and 2C19 underly the majority of patient variation to medicines seen in everyday medical practice and the widespread adoption of DNA testing for just these three enzymes will save tens of thousands of lives and billions of dollars every year. <br /><br />Howard Coleman, CEO<br />Genelex Corporation<br />Seattle, WA 98121Howard Colemanhttps://www.blogger.com/profile/07389886999829444049noreply@blogger.com